| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
Vol. 49, Issue 3, 279-295, September 1997
Department of Clinical Pharmacology, Berlex Laboratories, Inc.,
Montville, New Jersey
I. Introduction
II. Salient Features of Red Blood Cells
III. Principles and Definitions
IV. State of the Art
A. Methodological Aspects
B. Rate of Partitioning
C. Extent of Partitioning
D. Binding Sites
V. Significance of Studying Red Blood Cell Partitioning of Drugs
A. Rational Choice of Biological Fluid (Whole Blood, Red Blood
Cells, Plasma/Serum) for Assaying Drug Concentrations
B. Significance of Rate and Extent of Red Blood Cell Partitioning
for Physiological Interpretation of Organ Clearances and Volumes of
Distribution
C. Red Blood Cells as Probes for in Vivo Drug Distribution
D. Use of Red Blood Cell Suspensions in Plasma and Buffer to
Determine Plasma Protein Binding of Drugs
E. Significance of Studying the Effects of Drugs on Red Blood Cells
F. Red Blood Cells as Markers
VI. Conclusions
Acknowledgements
References
This article has been cited by other articles:
|
|
 |
|
  B. S. Zolnik, S. T. Stern, J. M. Kaiser, Y. Heakal, J. D. Clogston, M. Kester, and S. E. McNeil Rapid Distribution of Liposomal Short-Chain Ceramide in Vitro and in Vivo Drug Metab. Dispos., August 1, 2008; 36(8): 1709 - 1715. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 N. Perrottet, C. Robatel, P. Meylan, M. Pascual, J. P. Venetz, J. D. Aubert, M. M. Berger, L. A. Decosterd, and T. Buclin Disposition of valganciclovir during continuous renal replacement therapy in two lung transplant recipients J. Antimicrob. Chemother., June 1, 2008; 61(6): 1332 - 1335. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
X.-S. Miao, P. Song, R. E. Savage, C. Zhong, R.-Y. Yang, D. Kizer, H. Wu, E. Volckova, M. A. Ashwell, J. G. Supko, et al. Identification of the in Vitro Metabolites of 3,4-Dihydro-2,2-dimethyl-2H-naphthol[1,2-b]pyran-5,6-dione (ARQ 501; {beta}-Lapachone) in Whole Blood Drug Metab. Dispos., April 1, 2008; 36(4): 641 - 648. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. Yang, M. Jamei, K. R. Yeo, A. Rostami-Hodjegan, and G. T. Tucker Misuse of the Well-Stirred Model of Hepatic Drug Clearance Drug Metab. Dispos., March 1, 2007; 35(3): 501 - 502. [Full Text] [PDF]
|
|
|
|
|
|
H. M. Weiss, M. Fresneau, G. P. Camenisch, O. Kretz, and G. Gross IN VITRO BLOOD DISTRIBUTION AND PLASMA PROTEIN BINDING OF THE IRON CHELATOR DEFERASIROX (ICL670) AND ITS IRON COMPLEX FE-[ICL670]2 FOR RAT, MARMOSET, RABBIT, MOUSE, DOG, AND HUMAN Drug Metab. Dispos., June 1, 2006; 34(6): 971 - 975. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Sparreboom, A. C. Wolff, J. Verweij, Y. Zabelina, D. M. van Zomeren, G. L. McIntire, C. S. Swindell, R. C. Donehower, and S. D. Baker Disposition of Docosahexaenoic Acid-Paclitaxel, a Novel Taxane, in Blood: In Vitro and Clinical Pharmacokinetic Studies Clin. Cancer Res., January 1, 2003; 9(1): 151 - 159. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. W. Ward, J. W. Proksch, M. A. Levy, and B. R. Smith Development of an in Vivo Preclinical Screen Model to Estimate Absorption and Bioavailability of Xenobiotics Drug Metab. Dispos., January 1, 2001; 29(1): 82 - 88. [Abstract] [Full Text]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
 |
 |
 |
|
 |
 |
 |
